Wednesday, GSK Plc (NYSE:GSK) reported second-quarter sales of $9.95 billion (7.88 billion Sterling Pounds), up 10% year-over-year and 13% on constant currency. The analysts estimated sales of $9.66 billion. Vaccines’ sales decreased 1% at constant currency to 1.99 billion pounds, reflecting increased demand for Meningitis vaccines and uptake of Arexvy in the U.S. in line with expected waning seasonal demand.   Shingrix sales reached 832 million pounds, down 4% at constant currency, with Arexvy sales of 62 million pounds. Reuters noted that the vaccine sales came in below expectations. Also Read: Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail ...